Maastricht, Netherlands (Co-Chair)
ESMO Advanced Courses
Live interactive educational courses comprising of 1.5 to 2 days of plenary lectures and case-based sessions for experienced oncologists and specialists navigating complex clinical challenges
ABOUT ESMO ADVANCED COURSES 2026
ESMO Advanced Courses include in-person plenary lectures and case-based sessions with a multidisciplinary faculty of 8-10 international experts. The courses aim to address specific advanced challenges in patient management in different tumour settings and include in-depth, select lectures, workshops and interactive discussion seminars.
ESMO Advanced Courses cover a wide range of therapy areas
2026 ADVANCED COURSES CALENDAR
ESMO Advanced Course on Brain Metastases in Lung and Breast Cancer 2026: Barcelona
11-12 Nov 2026
Barcelona, Spain
Toronto, Canada
(Co-Chair)
Stockholm, Sweden (Co-Chair)
ESMO Advanced Course on Cholangiocarcinoma 2026: Barcelona
13-14 Nov 2026
Barcelona, Spain
Madrid, Spain
(Co-Chair)
Rennes, France
(Co-Chair)
ESMO Advanced Course on Early Drug Development 2026: Istanbul
23-24 Nov 2026
Instanbul, Türkiye
Melbourne, Australia
(Co-Chair)
Barcelona, Spain
(Co-Chair)
Hong Kong SAR, China
(Co-Chair)
Ankara, Türkiye
(Co-Chair)
ESMO Advanced Course on Defining Endocrine Sensitivity & Optimising Treatment Strategies in HR+/HER2- mBC Patients 2026: Barcelona
25-26 Nov 2026
Barcelona, Spain
Milan, Italy (Co-Chair)
Villejuif, France
(Co-Chair)
ESMO Advanced Course on Pancreatic Cancer: From Standard Treatment To Individualization 2026: Barcelona
27-28 Nov 2026
Barcelona, Spain
Villejuif, France
(Co-Chair)
Barcelona, Spain
(Co-Chair)
ESMO Advanced Course on HIV-Related Malignancies 2027: Cape Town
04-05 Feb 2027
Cape Town, South Africa
London, United Kingdom
(Co-Chair)
Johannesburg, South Africa (Co-Chair)
Programme coming soon
ESMO Advanced Course on Antibody-Drug Conjugates 2027: Lugano
11-12 Mar 2027
Lugano, Switzerland
Madrid, Spain
(Co-Chair)
London, United Kingdom
(Co-Chair)
Programme coming soon
ESMO Advanced Course on the Evolving Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative Early and Advanced Breast Cancer 2027: Beijing
23-24 Apr 2027
Beijing, China
Italy
(Co-Chair)
China
(Co-Chair)
Programme coming soon
ESMO ADVANCED COURSE METRICS 2025
594
57
58.7%
121
66
BENEFITS FOR OUR PARTNERS
FUNDING OPTIONS
Support type |
Funding amount per sponsor (EUR) |
|---|---|
| 100% funding Single sponsor | € 162,000 Per sponsor |
| 50% funding 2 sponsors | € 81,000 Per sponsor |


